Medytox Overview
- Year Founded
-
2000
- Status
-
Public
- Employees
-
761
- Stock Symbol
-
086900
- Investments
-
15
- Share Price
-
$51.83
- (As of Friday Closing)
Medytox General Information
Description
Medy-Tox Inc. is a Korea-based company engaged in the development, manufacture, and marketing of biopharmaceuticals. The company's main product is type-A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy.
Contact Information
Website
www.medytox.comCorporate Office
- 626 Teheran-ro, Medytox Building, Daechi-dong
- Gangnam-gu
- Seoul, Gangnam 06175
- South Korea
Corporate Office
- 626 Teheran-ro, Medytox Building, Daechi-dong
- Gangnam-gu
- Seoul, Gangnam 06175
- South Korea
Medytox Stock Performance
As of 20-Nov-2026, Medytox’s stock price is $51.83. Its current market cap is $335M with 6.46M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $51.83 | $54.79 | $45.53 - $98.58 | $335M | 6.46M | 24K | $1.57 |
Medytox Financials Summary
As of 30-Jun-2026, Medytox has a trailing 12-month revenue of $173M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 392,180 | 566,557 | 603,649 | 1,289,155 |
| Revenue | 173,006 | 173,764 | 167,558 | 169,124 |
| EBITDA | 5,346 | 18,202 | 28,041 | 24,984 |
| Net Income | 10,556 | 11,660 | 12,426 | 7,461 |
| Total Assets | 370,618 | 403,995 | 417,634 | 474,612 |
| Total Debt | 80,771 | 53,215 | 55,207 | 64,275 |
Medytox Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Medytox Comparisons
Industry
Financing
Details
Medytox Competitors (20)
One of Medytox’s 20 competitors is Regeneron Pharmaceuticals, a Formerly VC-backed company based in Tarrytown, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals | Formerly VC-backed | Tarrytown, NY | ||||
| Astellas Pharma | Corporation | Tokyo, Japan | ||||
| Genzyme Ireland | Corporation | Kilmeaden, Ireland | ||||
| Biocon Biologics | Formerly PE-Backed | Bengaluru, India | ||||
| Pfizer Pakistan | Corporation | Karachi, Pakistan |
Medytox Patents
Medytox Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026173467-A1 | Kit for detecting anti-botulinum toxin antibody and method for diagnosing and treating patients with secondary non-responsiveness to botulinum toxin using same | Pending | 14-Feb-2025 | ||
| WO-2026151300-A1 | Microorganism having hyaluronic acid-producing ability, variant thereof, method for producing hyaluronic acid using same, medium composition for microorganism, and method for producing hyaluronic acid using same | Pending | 10-Jan-2025 | ||
| WO-2026127707-A1 | Injectable composition for skin texture improvement and/or skin moisturization, comprising gamma-polyglutamic acid | Pending | 13-Dec-2024 | ||
| WO-2026101337-A1 | Composition including crosslinked polynucleotide as active ingredient | Pending | 07-Nov-2024 | ||
| WO-2025249959-A1 | Fusion protein and use thereof | Pending | 30-May-2024 | C07K14/70571 |
Medytox Signals
Medytox Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Medytox Investments & Acquisitions (15)
Medytox’s most recent deal was a Later Stage VC with Liflex Science for . The deal was made on 10-Nov-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Liflex Science | 10-Nov-2026 | Later Stage VC | Biotechnology | ||
| Aigen Sciences | 11-Jul-2025 | Early Stage VC | Drug Delivery | ||
| Aigen Sciences | 04-Oct-2022 | Seed Round | Drug Delivery | ||
| Lysentech | 22-Dec-2021 | Early Stage VC | Drug Discovery | ||
| Evolus | 01-Sep-2021 | Secondary Transaction - Private | Pharmaceuticals |
Medytox ESG
Risk Overview
Risk Rating
Updated November, 08, 2026
32.87 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Medytox Exits (1)
Medytox’s most recent exit was on 28-Jul-2021 from Cellapeutics Bio. The exit was categorized as with 5 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Cellapeutics Bio | 28-Jul-2021 | Completed |
|
Medytox Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Medytox Venture Investment | Seoul, South Korea | 2017 |
Medytox FAQs
-
When was Medytox founded?
Medytox was founded in 2000.
-
Where is Medytox headquartered?
Medytox is headquartered in Seoul, South Korea.
-
What is the size of Medytox?
Medytox has 761 total employees.
-
What industry is Medytox in?
Medytox’s primary industry is Pharmaceuticals.
-
Is Medytox a private or public company?
Medytox is a Public company.
-
What is Medytox’s stock symbol?
The ticker symbol for Medytox is 086900.
-
What is the current stock price of Medytox?
As of 20-Nov-2026 the stock price of Medytox is $51.83.
-
What is the current market cap of Medytox?
The current market capitalization of Medytox is $335M.
-
What is Medytox’s current revenue?
The trailing twelve month revenue for Medytox is $173M.
-
Who are Medytox’s competitors?
Regeneron Pharmaceuticals, Astellas Pharma, Genzyme Ireland, Biocon Biologics, and Pfizer Pakistan are some of the 20 competitors of Medytox.
-
What is Medytox’s annual earnings per share (EPS)?
Medytox’s EPS for 12 months was $1.57.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process